Answers are grounded in this paper and cite their sources.
Rivaroxaban may be a viable oral alternative to parenteral factor-IIa inhibitors for treating heparin-induced thrombocytopenia with severe thrombotic complications.
Heparin-induced thrombocytopenia (HIT) is a life or limb-threatening thrombotic thrombocytopenia. HIT is traditionally treated with factor-IIa inhibitors such as bivalirudin, lepirudin, or argatroban. However, these agents usually require parenteral administration and are not generally available in all countries. Recently, several experiences with novel oral anticoagulants (NOACs) administration to treat HIT had been reported. NOACs generally offer advantages such as consistent and predictable anticoagulation, oral administration with good patient compliance, and a good safety profile. We report a case of HIT with severe thrombotic complications successfully treated with rivaroxaban and discuss the current knowledge about the use of NOACs for the treatment of this potentially fatal thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Samoš et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: